Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: A case report

Ikenouchi, Atsuko; Yoshimura, Reiji; Ikemura, Naomi; Utsunomiya, Kensuke; Mitoma, Masae; Nakamura, Jun

doi:10.1016/j.pnpbp.2006.03.006

Cited by 15 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with a previous study suggesting that plasma HVA and MHPG levels are associated with psychotic or excitement symptoms in patients with schizophrenia 7. Moreover, a previous report8 has demonstrated that plasma levels of HVA and MHPG were increased in systemic lupus erythematosus patients with psychiatric symptoms, which is consistent with our findings. The findings in this case suggest that dopaminergic and noradrenergic functions might play a role in the development of psychotic symptoms in patients with HE, and plasma levels of HVA and MHPG might be useful as state markers.…”

Section: Discussionsupporting

confidence: 94%

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Horikoshi

Miura²,

Kunii³

et al. 2017

NDT

View full text Add to dashboard Cite

Hashimoto encephalopathy (HE) is believed to be an immune-mediated disorder associated with Hashimoto’s thyroiditis. It was suggested that neuropsychiatric symptoms, the presence of antithyroid antibody, and good response to steroids were important for the diagnosis of HE. It has been reported that homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), which are monoamine metabolites of dopamine and noradrenaline, respectively, are the possible biomarkers of neuropsychiatric diseases. We report a case of Hashimoto encephalopathy, in which we longitudinally measured the plasma levels of monoamine metabolites. A 52-year-old woman developed acute psychosis, and was admitted to the psychiatric ward of our hospital due to psychotic state, 6 days after a traffic accident. An extensive evaluation showed no remarkable findings, except an increase in antithyroglobulin antibodies. Plasma levels of HVA and MHPG were extremely high at 66.5 and 41.8 ng/mL, respectively. On day 16, 50 mg/day oral prednisolone was administered, which improved her psychotic symptoms. Plasma levels of HVA and MHPG decreased to 7.2 and 9.9 ng/mL, respectively, on day 19. After the temporary worsening of psychosis and increase in plasma levels of HVA and MHPG, the dosage of prednisolone was tapered and low-dose risperidone was started. Her psychiatric symptoms gradually improved and plasma monoamine metabolite levels decreased again (HVA: 17.9 ng/mL; MHPG: 7.7 ng/mL). Although autoimmune mechanism has been suggested to be involved in HE, neural mechanism and pathogenesis of HE remain unknown. Our findings suggest that monoaminergic neural activity might be associated with psychotic symptoms in patients with HE and plasma levels of monoamine metabolites might be useful as state markers.

show abstract

Section: Discussionsupporting

confidence: 94%

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Horikoshi

Miura²,

Kunii³

et al. 2017

NDT

View full text Add to dashboard Cite

show abstract

“…Serum BDNF levels did not correlate with SLEDAI score. Only one previous case report has been described of psychotic involvement in SLE with an increase of serum BDNF [61]. Likewise, in multiple sclerosis and rheumatoid arthritis, a decrease in serum BDNF levels occurs with clinical improvement, independently of other inflammatory markers [62,63].…”

Section: Discussionmentioning

confidence: 99%

Serum and Lymphocytic Neurotrophins Profiles in Systemic Lupus Erythematosus: a Case-Control Study

et al. 2013

View full text Add to dashboard Cite

BackgroundNeurotrophins play a central role in the development and maintenance of the nervous system. However, neurotrophins can also modulate B and T cell proliferation and activation, especially via autocrine loops. We hypothesized that both serum and lymphocytic neurotrophin levels may be deregulated in systemic Lupus erythematosus (SLE) and may reflect clinical symptoms of the disease.MethodsNeurotrophins in the serum (ELISA tests) and lymphocytes (flow cytometry) were measured in 26 SLE patients and 26 control subjects. Th1 (interferon-γ) and Th2 (IL-10) profiles and serum concentration of BAFF were assessed by ELISA in the SLE and control subjects.FindingsWe have demonstrated that both NGF and BDNF serum levels are higher in SLE patients than healthy controls (p=0.003 and p<0.001), independently of Th1 or Th2 profiles. Enhanced serum NT-3 levels (p=0.003) were only found in severe lupus flares (i.e. SLEDAI ≥ 10) and significantly correlated with complement activation (decreased CH 50, Γ=-0.28, p=0.03). Furthermore, there was a negative correlation between serum NGF levels and the number of circulating T regulatory cells (Γ=0.48, p=0.01). In circulating B cells, production of both NGF and BDNF was greater in SLE patients than in healthy controls. In particular, the number of NGF-secreting B cells correlated with decreased complement levels (p=0.05). One month after SLE flare treatment, BDNF levels decreased; in contrast, NGF and NT-3 levels remained unchanged.ConclusionThis study demonstrates that serum and B cell levels of both NGF and BDNF are increased in SLE, suggesting that the neurotrophin production pathway is deregulated in this disease. These results must be confirmed in a larger study with naive SLE patients, in order to avoid the potential confounding influence of prior immune-modulating treatments on neurotrophin levels.

show abstract

“…Therefore, serum BDNF levels in the present case were lower compared with those in normal volunteers and even in depressed patients. In contrast, in a case of NPSLE with reversible organic brain changes, we reported that the plasma BDNF levels were raised during the period when the patient's psychotic symptoms deteriorated, and the plasma BDNF levels were normalized in parallel with the recovery of her organic brain changes and improvement in her psychotic symptoms (Ikenouchi et al 2006). In addition, Frey and colleagues (2006) reported that long term treatment with valproic acid increased hippocampal BDNF levels in rats, and Park and colleagues (2006) demonstrated that long term quetiapine administration attenuated the decreased BDNF mRNA expression in both the hippocampal and cortical regions of rats caused by immobilization stress.…”

Section: Discussionmentioning

confidence: 63%

“…Neuropsychiatric syndromes of SLE (NPSLE) patients often reveal various psychiatric features such as delirium, cognitive blunting, psychosis, and affective disorder (ACR 1999). Recently, we had reported that serum BDNF levels were increased in the presence of severe psychiatric symptoms and organic changes in the brain (Ikenouchi et al 2006). In that case, serum BDNF levels were normalized in parallel with recovering organic brain changes and improving their associated psychotic symptoms.…”

Section: Introductionmentioning

confidence: 95%

Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes

Ikenouchi-Sugita

Yoshimura

Ueda³

et al. 2008

NDT

Self Cite

View full text Add to dashboard Cite

Abstract:In the present study, the authors reported on a case in neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) with irreversible organic brain changes. The authors also longitudinally investigated serum brain-derived neurotrophic factor (BDNF) levels in the patient. We found that serum BDNF levels in the NPSLE patient with irreversible organic brain change were consistently low, independent of the severity of psychiatric symptoms. Thus, the longitudinal measurement of serum BDNF levels might be useful in predicting the prognosis of NPSLE.

show abstract

Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: A case report

Cited by 15 publications

References 28 publications

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Serum and Lymphocytic Neurotrophins Profiles in Systemic Lupus Erythematosus: a Case-Control Study

Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes

Contact Info

Product

Resources

About